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in ex-, current- and never-smoking asthmatics
Eef D Telenga1,2, Huib A M Kerstjens1,2, Nick H T ten Hacken1,2, Dirkje S Postma1,2 and Maarten van den Berge1,2*Abstract
Background: It has been suggested that smoking asthmatics benefit less from corticosteroid treatment than never-
smoking asthmatics. We investigated differences in blood and sputum inflammatory profiles between ex-, current-,
and never-smokers and assessed their ICS treatment response after 2-week and 1-year treatment.
Methods: We analyzed FEV1, PC20 methacholine and PC20 AMP, (differential) cell counts in sputum and blood in
ex-, current- and never-smokers at baseline (n=114), after 2-week treatment with fluticasone 500 or 2000 μg/day
(n=76) and after 1-year treatment with fluticasone 500 μg/day or a variable dose of fluticasone based on a self-
management plan (n=64).
Results: A total of 114 patients were included (29 ex-, 30 current- and 55 never-smokers. At baseline, ex- and
current-smokers had less eosinophils in sputum and blood than never-smokers. Blood neutrophil counts were
higher in current- than in never-smokers. A higher number of cigarettes smoked daily was associated with lower
blood and sputum eosinophils. After 2-week ICS treatment, FEV1 %predicted improved less in current-smokers than
never-smokers (2.4% versus 8.1%, p=0.010) and ex-smokers tended to improve less than never-smokers (4.1%,
p=0.067). In contrast, no differences in ICS treatment response in lung function or inflammatory cells were found
between the three groups after 1 year.
Conclusions: Ex- and current-smokers have less eosinophils and more neutrophils in their sputum and blood than
never-smokers. Although ex- and current-smokers have a reduced short-term corticosteroid treatment response, we
did not find a difference in their long-term treatment response.
Keywords: Asthma, Smoking, Corticosteroid responsiveness, Lung functionBackground
Asthma is a chronic inflammatory airway disease in which
a variety of inflammatory cells and mediators play a role.
Inhaled corticosteroids (ICS) are the cornerstone of treat-
ment, since they exert broad anti-inflammatory effects.
They have been shown to improve symptoms and lung
function as well as bronchial hyperresponsiveness and
markers of airway inflammation in blood, induced sputum
and bronchial biopsies [1]. In addition, the use of ICS re-
duces the number of asthma exacerbations [2].
About 20-30% of asthma patients smoke and another
20-40% are ex-smokers [3-6]. Current-smokers appear to
have a different airway inflammatory profile than never-* Correspondence: m.van.den.berge@umcg.nl
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Groningen, Netherlands
2Groningen Research Institute for Asthma and COPD, University of
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reproduction in any medium, provided the orsmokers, with less eosinophilic and more neutrophilic
inflammation [7-12]. Thus far, very little is known about
the inflammatory profile of ex-smokers.
The few studies investigating the effects of smoking on
the short-term efficacy of oral or inhaled corticosteroid
treatment in asthma, demonstrate that the forced expira-
tory volume in one second (FEV1) improves significantly
in never-smokers, but not in current-smokers [7,13-15].
However, none of these studies found statistically signifi-
cant differences in improvement in FEV1 when directly
comparing never- and current-smokers. The only study
that included ex-smokers, showed no improvement in
FEV1 or asthma control after 2-week oral corticosteroid
treatment in ex- and current-smokers [15].
We aimed to investigate whether ex-, current- and
never-smokers with asthma have different inflammatory
profiles and if current number of cigarettes or packyearsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the short- and long-term responsiveness to corticoste-
roids after 2-week and 1-year treatment is different be-
tween ex-, current- and never-smoking asthmatics. We
have analyzed this in a relatively large group of 114 well-




Patients with a diagnosis of asthma, 18–65 years old,
were included if they met the following criteria: provoca-
tive concentration of methacholine inducing a 20% fall
of FEV1 (PC20 methacholine) ≤8 mg/ml, at least one
positive skin-prick test out of 17 common aero-allergens,
reversibility to salbutamol 200 μg ≥9% of the predicted
FEV1 and the ability to expectorate sputum after hyper-
tonic saline inhalation. This study was conducted in ac-
cordance with the amended declaration of Helsinki and
the study was approved by the medical ethics committee
of the University Medical Center Groningen and all par-
ticipants gave their written informed consent.
Study design
Figure 1 shows the outline of the study. ICS were tapered
before enrollment in the study, as described in the original
manuscript [16]. After discontinuation of ICS completely
for three weeks, or earlier, if they experienced symptoms
of an asthma exacerbation, patients were randomized to 3
treatment arms, with minimization according to smoking
status, age, previous dose of ICS, FEV1 %predicted, revers-
ibility after 200 μg of salbutamol, PC20 methacholine, and
serum IgE. Patients were first treated for 2 weeks withFigure 1 Flow-chart of the study. FEV1 = forced expiratory volume in on
AMP = adenosine-5′-monophosphate.either prednisolone 30 mg/day, fluticasone 500 μg/day or
fluticasone 2000 μg/day via Diskhaler, followed by another
50 weeks of treatment as follows.
The prednisolone 30 mg/day group was treated
according to a self-management plan. They first received
fluticasone 200 μg/day and were instructed to change the
dose according to a self-management plan (see Additional
file 1: Table S1). The fluticasone 500 μg/day group contin-
ued with the same dose for another 50 weeks. The
fluticasone 2000 μg/day arm followed a program with
step-down and eventually complete discontinuation of
corticosteroids. The latter is not in agreement with the
current guidelines and therefore this arm was removed
from our long-term analyses. During the first 2 weeks, the
study had a double-blind, double-dummy design, followed
by 50 weeks open label treatment. Rescue medication
consisted of salbutamol 400 μg via Diskhaler. No other
concomitant pulmonary medication was allowed.
Patients with an exacerbation were treated with a stan-
dardized 7-day course of oral prednisolone. Patients
were withdrawn if they required >1 hospitalization, >4
courses of oral prednisolone or >2 courses within 3
months. Requirement of >2000 μg fluticasone in the
self-management group additionally led to withdrawal.
Lung function and bronchial hyperresponsiveness
FEV1 was measured with a calibrated, water-sealed spir-
ometer according to standardized guidelines before and
20 minutes after 200 μg of salbutamol [17]. Provocation
tests were performed using a 2-minute tidal breathing
method, adapted from Cockcroft and coworkers [18].
After an initial nebulized saline challenge, subjects in-
haled doubling concentrations of the provocative agente second, PC20 = provocative concentration causing a 20% fall in FEV1,
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5′-monophosphate (AMP) 0.04 to 320 mg/ml) at 5 minute
intervals. All calculations of PC20 were performed with a
base-2 logarithm, reflecting doubling concentrations and
normalizing the distribution.Sputum induction and processing
Sputum was induced by inhalation of hypertonic saline as
previously described [16]. Fifteen minutes after salbutamol
(200 μg) inhalation, hypertonic saline (3%, 4%, and 5%)
was nebulized for each concentration during 7 minutes.
Whole samples were processed according to the method
of Fahy et al. with some modifications [19].
Cell counts in blood were performed by flow cytometry.
Eosinophilic cationic protein (ECP) in serum and sputum
were measured with a fluoroenzyme assay (ImmunoCAP
ECP, Pharmacia, Uppsala, Sweden). Exhaled nitric oxide
(NO) was measured by tidal breathing method using a
chemiluminescence analyzer (CLD 700 AL, ECO physics,
Switzerland) as described previously [16].Statistical methods
In case of non-normal distribution, log-transformation
was performed to obtain normally distributed variables.
Baseline differences between ex-, current- and never-
smokers were tested by analysis of variance (ANOVA),
Kruskal-Wallis or Chi-square test. If a significant differ-
ence between the three groups was found, we performed
post-hoc tests with Holm’s Bonferroni correction for
multiple testing. Short-term treatment effects were ana-
lyzed only in the two groups using ICS (i.e. fluticasone
2000 μg/day or 500 μg/day). To test for changes after
treatment within a group (i.e. ex-, current- or never-
smokers), we performed paired t-tests. To test for differ-
ences in corticosteroid treatment responsiveness between
groups, we performed linear regression analyses with
change from baseline of each variable as outcome vari-
able and smoking status as the predictor variable and
age, gender and type of treatment as covariates. In
addition, we adjusted for the baseline value of each
variable, since this has been shown to be one of the
major predictors of treatment response [20]. To test
the effect of current and cumulative smoke exposure
on baseline differences and treatment response, we
performed linear regression analyses with either the
number of cigarettes/day or packyears as predictor vari-
ables. We added age as a covariate in these analyses.
The reported correlation coefficient (b) signifies the
change in an outcome variable (e.g. FEV1) for every
unit increase of the predictor variable (e.g. cigarettes/
day). In all regression analyses with absolute FEV1 we
corrected for age, gender and height.Results
Patient characteristics
114 patients were included, 29 ex-smokers, 30 current-
smokers and 55 never-smokers. Their baseline charac-
teristics, after tapering of ICS (visit 2), are presented in
Table 1. During the ICS tapering period, 16 patients
returned to the hospital earlier due to symptoms com-
patible with an asthma exacerbation. From these 16 pa-
tients, 6 still used ICS at the start of the treatment
period (2 ex-smokers, 2 current-smokers and 2 never-
smokers) with a median beclomethasone equivalent dose
of 450 μg/day (range 400 – 800 μg/day); the remaining
10 patients had discontinued ICS completely for a me-
dian period of 12 days (range 2 – 21 days). Ex-smokers
had a median smoking cessation period of 7 years (inter-
quartile range (IQR) 1.5 -15.5 years) and had smoked a
median of 6.9 packyears (IQR 3.5 – 20.8). Current-
smokers had smoked 7.4 packyears (IQR 2.5 – 14.1) and
smoked a median of 8.0 cigarettes/day (IQR 4.6 – 15.0).
Baseline differences between ex-, current- and never-
smokers
Ex-smoking asthmatics were significantly older than
current- and never-smokers (median 38 versus 27 and
25 years, respectively; p=0.001). Sputum eosinophil per-
centages and blood eosinophil counts were significantly
lower in ex- and current-smokers than in never-smokers.
Serum ECP, a marker of eosinophil activation, was signifi-
cantly lower in ex- than never-smokers. Blood neutrophil
counts were higher in current- than in never-smokers.
Blood neutrophil counts of ex-smokers were between
those of never- and current-smokers, but not significantly
different from either group. FEV1, reversibility to salbuta-
mol, bronchial hyperresponsiveness to methacholine or
AMP and exhaled NO were comparable between ex-,
current- and never-smokers.
Association between current and cumulative smoke
exposure and baseline clinical and inflammatory
parameters
In current-smokers, a higher number of cigarettes smoked
daily was associated with lower sputum eosinophil percent-
ages, blood eosinophil counts and serum ECP (Table 2).
Furthermore, it was associated with less severe bronchial
hyperresponsiveness to both methacholine and AMP (0.1
doubling dose per cigarette/day for methacholine and 0.2
doubling concentrations per cigarette/day for AMP). In ex-
and current-smokers, a higher number of packyears was
associated with a lower FEV1 %predicted (p=0.034).
Short-term efficacy of ICS treatment in ex-, current- and
never-smokers
76 patients were treated with fluticasone 2000 μg/day or
500 μg/day. After 2-week treatment, FEV1 %predicted
Table 1 Differences in clinical and inflammatory variables between ex-, current- and never-smokers at baseline
Ex-smokers (n=29) Current-smokers (n=30) Never-smokers (n=55) p-value
Age (years) 38 (28, 41) 27‡ (25, 37) 25‡ (25, 35) 0.001
Gender (male/female)# 13 / 16 10 / 20 16 / 39 0.349
Daily number of cigarettes – 8.0 (4.6, 15.0) –
Packyears (number) 6.9 (3.5, 20.8) 7.4 (2.5, 14.1) –
Duration of smoking cessation (years) 7.0 (1.5, 15.5) – –
Still using ICS after tapering (yes/no)# 2 / 27 2 / 28 2 / 53 0.645
Treatment# (prednisolone/FP500/FP2000) 10 / 11 / 8 11 / 6 / 13 17 / 20 / 18 0.508
FEV1 (L) 2.9 (2.3, 3.4) 2.8 (2.4, 3.4) 3.0 (2.3, 3.4) 0.911
FEV1 (%predicted) 79 (68, 89) 78 (70, 91) 82 (62, 94) 0.957
Reversibility (%predicted) 11 (9, 17) 11 (9, 15) 13 (9, 18) 0.150
PC20 methacholine (mg/ml)
§ 0.7 (0.06, 7.9) 0.8 (0.03, 7.3) 0.4 (0.02, 7.8) 0.123
PC20 AMP (mg/ml)
§ 10.3 (0.2, 640) 7.2 (0.2, 640) 3.6 (0.02, 640) 0.179
Sputum eosinophils (%) 2.8* (1.1, 6.0) 4.7* (0.8, 10.7) 7.7 (3.8, 14.3) 0.015
Blood eosinophils (109/L) 0.27* (0.14, 0.43) 0.28* (0.15, 0.41) 0.44 (0.34, 0.61) 0.001
Sputum ECP (μg/L) 33 (19, 124) 67 (16, 126) 49 (17, 163) 0.979
Serum ECP (μg/L) 10* (8, 17) 14 (9, 23) 22 (12, 29) 0.001
Sputum neutrophils (%) 39 (22, 53) 42 (26, 65) 29 (20, 50) 0.175
Blood neutrophils (109/L) 3.9 (3.0, 4.6) 4.1* (3.4, 5.3) 3.1 (2.6, 4.1) 0.003
Exhaled NO (ppb) 15 (11, 21) 12 (6, 17) 16 (12, 21) 0.058
Values are presented as medians with interquartile ranges, unless stated otherwise, # = number, § geometric mean (range), prednisolone = prednisolone 30 mg once
daily, FP500 fluticasone propionate 500 μg/day, FP2000 fluticasone propionate 2000 μg/day, FEV1 forced expiratory volume in one second, PC20 provocative
concentration causing a 20% fall in FEV1, AMP adenosine-5′-monophosphate, ECP eosinophilic cationic protein, NO nitric oxide, ppb parts per billion, * = p<0.05
compared to never-smokers with Holm’s Bonferroni correction, ‡ = p<0.05 compared to ex-smokers with Holm’s Bonferroni correction.
Table 2 Association between the amount of smoke
exposure, as reflected by the number of cigarettes
smoked daily and number of packyears and clinical and
inflammatory variables at baseline
Cigarettes/day Packyears
b p-value b p-value
FEV1 (L) 0.13 0.508 –0.01 0.450
FEV1 (%predicted) 0.06 0.897 –0.31 0.034
Reversibility
(%predicted)
–0.22 0.162 –0.00 0.968
PC20 methacholine
(doubling concentrations)
0.11 0.050 0.04 0.123
PC20 AMP
(doubling concentrations)
0.19 0.031 0.02 0.593
Sputum eosinophils (%)* –0.06 0.024 –0.01 0.496
Blood eosinophils (109/L)* –0.02 0.021 0.00 0.645
Sputum ECP (μg/L)* –0.04 0.313 –0.00 0.839
Serum ECP (μg/L)* –0.04 0.025 0.00 0.829
Sputum neutrophils (%)* –0.00 0.779 0.00 0.713
Blood neutrophils (109/L)* 0.00 0.673 –0.00 0.338
Exhaled NO (ppb) –0.09 0.708 0.10 0.254
b = unstandardized regression coefficient, FEV1 forced expiratory volume in
one second, PC20 provocative concentration causing a 20% fall in FEV1,
AMP adenosine-5′-monophosphate, ECP eosinophilic cationic protein,
NO nitric oxide, ppb parts per billion, * variable log-transformed.
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p<0.001, Table 3), but not in ex- or current-smokers
(4.1%, p=0.073 and 2.4%, p=0.172 respectively). The
magnitude of improvement in FEV1 %predicted was sig-
nificantly lower in current- than in never-smokers
(p=0.010, Figure 2A) and tended to be lower in ex- than
in never-smokers (p=0.067). Sputum eosinophil per-
centages and ECP concentrations improved less in
current- than never-smokers and tended to improve
less in ex- than never-smokers. No significant diffe-
rences in short-term ICS-induced improvements in
bronchial hyperresponsiveness and exhaled NO were
observed between the three groups. A higher number
of packyears smoked was associated with less improve-
ment in FEV1 %predicted (−0.55% per packyear,
p=0.025, Additional file 1: Table S1). The number of
cigarettes smoked daily was not associated with the
short-term ICS response in current-smokers.Long-term efficacy of ICS treatment in ex-, current- and
never-smokers
Data from 64 patients treated for 1-year with fluticasone
500 μg/day or a variable dose of fluticasone according to
the self-management plan were available (Table 4). In
the self-management group, the median daily dose of








Age (years) 38 (28, 44) 27 (25, 42) 25 (25, 36)
Gender (male/female) 9 / 10 4 / 15 12 / 26
Treatment (FP500/FP2000) 11 / 8 6 / 13 20 / 18
ΔFEV1 (L) 0.14 (-0.07, 0.31) 0.051 0.08
* (-0.05, 0.32) 0.113 0.30 (0.18, 0.77) <0.001
ΔFEV1 (%predicted) 4.1
# (-2.1, 9.2) 0.073 2.4* (-4.7, 8.7) 0.172 8.1 (4.6, 20.4) <0.001
ΔReversibility (%predicted) -4.8 (-8.1, -0.3) 0.022 -4.3 (-7.9, 2.3) 0.025 -6.8 (-9.7, -2.9) <0.001
ΔPC20 methacholine (doubling concentrations) 1.3
# (0.4, 2.0) 0.001 1.4 (0.3, 2.4) 0.001 2.3 (1.1, 3.2) <0.001
ΔPC20 AMP (doubling concentrations) 3.1 (0.4, 5.7) 0.001 0.9
# (0.1, 5.6) 0.007 5.1 (2.2, 6.4) <0.001
ΔSputum eosinophils (%) -1.4 (-5.7, -0.7) <0.001 -1.0‡ (-4.5, 0.0) 0.004 -6.3 (-14.5, -2.2) <0.001
ΔBlood eosinophils (109/L) -0.05 (-0.16, 0.02) 0.018 -0.02 (-0.15, 0.03) 0.060 -0.16 (-0.28, -0.01) 0.002
ΔSputum ECP (μg/L) -12 (-82, -1) 0.022 -10*§ (-48, 9) 0.219 -31 (-135, -1) <0.001
ΔSerum ECP (μg/L) -1.3 (-4.5, 2.1) 0.564 -2.4# (-15.0, -4.2) 0.303 -6.9 (-14.6, -1.0) <0.001
ΔSputum neutrophils (109/L) -3.3 (-17.4, 7.8) 0.270 -2.7§ (-15.0, 4.2) 0.496 0.5 (-7.8, 6.3) 0.382
ΔBlood neutrophils (109/L) 0.31 (-0.57, 0.78) 0.625 0.27§ (-0.47, 0.97) 0.902 0.22 (-0.26, 0.79) 0.563
ΔExhaled NO (ppb) -3.3 (-6.8, 0.00) 0.039 -3.6 (-6.8, 3.1) 0.248 -5.1 (-8.4, -2.1) <0.001
Values are presented as median change from baseline with interquartile range. ICS inhaled corticosteroids, FP500 fluticasone propionate 500 μg/day,
FP2000 fluticasone propionate 2000 μg/day, FEV1 forced expiratory volume in one second, PC20 provocative concentration causing a 20% fall in FEV1,
AMP adenosine-5′-monophosphate, ECP eosinophilic cationic protein, NO nitric oxide, ppb parts per billion,* Significantly different from never-smokers (p<0.05),
# Trend for difference from never-smokers (0.05<p≤0.1), ‡ Significantly different from ex-smokers (p<0.05), § Trend for difference from ex-smokers (0.05<p≤0.1).
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(range 200–1375 μg/day), which was significantly lower
than the 500 μg/day used by the fixed-dose group. The
level of FEV1 %predicted improved significantly in ex- and
never-smokers, (5.1%, p=0.011 and 10.2%, p<0.001 re-
spectively) and tended to improve in current-smokers
(3.1%, p=0.058). There was no significant difference in the
magnitude of improvement in FEV1 between the three
groups (Figure 2B). The treatment-induced changes in
PC20 methacholine and numbers and percentages of in-
flammatory cells in blood and sputum did also not differ
significantly between ex-, current- and never-smokers. A
higher number of packyears was associated with less im-
provement in FEV1 %predicted (p=0.032, Additional file 1:
Table S2). In addition, the severity of PC20 methacholine
improved less with a higher number of packyears smoked
(p=0.043). The number of cigarettes smoked daily was not
associated with the magnitude of improvement in FEV1
or PC20 methacholine.
Effect of inflammation on improvement in lung function
To investigate if the baseline type and level of inflamma-
tion was associated with the corticosteroid treatment
response, we analyzed the independent associations
between the improvement in FEV1 %predicted after
2-week and 1-year ICS treatment and eosinophils in
sputum and blood and smoking status. Sputum: higher
percentages of sputum eosinophils were significantly as-
sociated with a greater improvement in FEV1 %predictedboth after 2-week and 1-year treatment (b = 0.252,
p= 0.005 and b=0.232, p=0.002 respectively, Additional
file 1: Table S3), whereas sputum neutrophils were not
independently associated with improvement in FEV1
%predicted. Blood: higher levels of blood eosinophil
and lower levels of blood neutrophils were independ-
ently associated with a higher improvement in FEV1
%predicted after 2-week ICS treatment (b=0.529,
p=0.022 and b=−0.343, p=0.049 respectively, Additional file 1:
Table S4). After 1 year ICS treatment blood eosinophil levels
were still significantly associated with improvement in FEV1
%predicted. Smoking status was not significantly associated
with improvement in FEV1 %predicted, when inflammation
was taken into account (Additional file 1: Tables S3 and S4).
Discussion
Our study shows that current-smokers with asthma have
a different type of inflammation, i.e. they have less eosino-
phils and more neutrophils in their sputum and blood
than never-smokers, even though the severity of airflow
obstruction and bronchial hyperresponsiveness is compar-
able. Moreover, a higher number of cigarettes smoked
daily was associated with a lower percentage of eosino-
phils in sputum, suggesting that the type of airway inflam-
mation may be influenced by the amount of smoke
exposure. Interestingly, the inflammatory profile of a
group of asthmatics with a median smoking cessation of 7
years was more similar to that of the current-smoking
than that of the never-smokers, suggesting that effects of
Figure 2 Change in FEV1 % predicted after 2-week and 1-year treatment with ICS. A = 2-week treatment, B = 1-year treatment,
FEV1 = forced expiratory volume in one second.
Telenga et al. BMC Pulmonary Medicine 2013, 13:58 Page 6 of 9
http://www.biomedcentral.com/1471-2466/13/58smoking may persist for a long time after smoking cessa-
tion in asthmatics. Additionally, we show that current-
smokers have a blunted short-term corticosteroid treatment
response. Again, ex-smokers are more similar to current-smokers than to never-smokers, with a trend for a
blunted response. However, we found no evidence for a
blunted response in both ex- and current-smokers on
the long-term.








Age (years) 37 (27, 40) 29 (25, 36) 25 (25, 34)
Gender (male/female) 9 / 12 7 / 10 10 / 27
Treatment (FP500/self management) 11 / 10 6 / 11 20 / 17
ΔFEV1 (L) 0.15 (0.00, 0.60) 0.010 0.17 (-0.07, 0.82) 0.052 0.35 (0.22, 0.71) <0.001
ΔFEV1 (%predicted) 5.1 (0.4, 13.9) 0.011 3.1 (-1.7, 21.5) 0.058 10.2 (6.4, 20.1) <0.001
ΔPC20 methacholine (doubling concentrations) 2.7 (1.5, 5.7) 0.002 2.3 (1.4, 3.1) <0.001 4.4 (2.1, 5.5) <0.001
ΔSputum eosinophils (%) -2.7 (-4.5, -0.3) 0.005 -2.0 (-14.3, -0.1) 0.029 -7.0 (11.9, -1.3) <0.001
ΔBlood eosinophils (×109/L) -0.04 (-0.05, 0.02) <0.001 -0.04 (-0.08, 0.05) <0.001 -0.16 (-0.26, -0.04) <0.001
ΔSputum ECP (μg/L) 11 (-5, 33) 0.194 -11 (-165, 6) 0.096 -19 (-73, 3) 0.023
ΔSerum ECP (μg/L) 0.1 (-3.1, 2.3) 0.576 -1.8 (-12.8, 2.9) 0.268 -9.2 (-19.3, -4.1) <0.001
ΔSputum neutrophils (109/L) 8.5 (-18.2, 23.3) 0.126 4.8 (-22.2, 24.3) 0.641 6.9 (-5.1, 24.6) 0.077
ΔBlood neutrophils (109/L) 0.32 (-0.51, 0.70) <0.001 -0.15 (-0.87, 0.21) <0.001 -0.40 (-0.78, 0.39) <0.001
ΔExhaled NO (ppb) -4.9 (-7.1, 2.1) 0.182 -6.1 (-9.3, 2.9) 0.033 -4.4 (-7.9, -1.4) 0.002
Values are presented as median change from baseline with interquartile range. ICS inhaled corticosteroids, FP500 fluticasone propionate 500 μg/day,
FEV1 forced expiratory volume in one second, PC20 provocative concentration causing a 20% fall in FEV1, AMP adenosine-5′-monophosphate,
ECP eosinophilic cationic protein, NO nitric oxide, ppb parts per billion.
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had less improvement in FEV1 than never-smokers, as
reported earlier [7,13,15]. We extend these findings by
showing that ex-smokers also tend to respond less to
corticosteroid treatment than never-smokers on the
short-term. Thus far, the efficacy of corticosteroid treat-
ment in ex-smokers has only been investigated in one
study with 15 asthmatic ex-smokers [15]. Comparable to
our findings, they observed that the short-term improve-
ment in FEV1 after 2-week treatment with oral cortico-
steroids in ex-smokers was intermediate between
current- and never-smokers.
Interestingly, we found that the long-term effects of 1-
year ICS treatment were not significantly different in ex-
and current-smokers compared to never-smokers.
This observation is in line with a study in 492 current-
and 2,432 never-smokers, showing that 400 μg/day
budesonide or placebo for 3 years was equally effective
in current- and never-smokers [21]. Furthermore, in a
large, real-life study in 619 asthmatics, the level of im-
provement in FEV1 and asthma control was similar in
ex-, current- and never-smokers after 1-year treatment
with small particle budesonide/formoterol formulation
[22]. Taken together, these findings suggest that ex-
and current-smokers with asthma have a lower cor-
ticosteroid treatment response on the short-term than
never-smoker, whereas the long-term response is similar
between the three groups. We extend these observations by
showing that 1-year ICS treatment response is not driven
by smoking per se. Rather the underlying inflammatory
process present drives the ICS response over 1 year, i.e. a
better response with higher sputum and blood eosinophils,independent of smoking. In this context, the findings of
Tomlinson and colleagues are of interest [14]. They found
a reduced short-term response to inhaled beclomethasone
in current-smokers with asthma, which could be over-
come by increasing the dose of beclomethasone from
400 μg/day to 2000 μg/day. It is tempting to speculate
that the blunted corticosteroid treatment response in ex-
and current-smokers can also be overcome by prolonged
treatment, although this remains to be formally demon-
strated in future prospective studies.
We did not find any differences in the level of lung
function or severity of bronchial hyperresponsiveness
between ex-, current- and never-smokers at baseline.
However, we did observe a lower level of eosinophilic in-
flammation in blood and sputum and higher blood neu-
trophil counts in current-smokers than in never-smokers.
These findings are consistent with earlier studies [7-12].
Additionally, we demonstrated that the level of eosino-
philic inflammation was also lower in ex-smokers and very
similar to that seen in current-smokers. To date, only one
other study, also from our research group, reported on the
inflammatory profile in ex-smoking asthmatics [23]. This
study demonstrated that ex-smoking asthmatics have
lower percentages of eosinophils in airway wall biopsies
than never-smokers and that the percentage of sputum
neutrophils is significantly higher in ex- than in never-
smokers. The above findings suggest that smoking does
not only have an acute effect on airway inflammation, but
also a chronic effect that may persist for years after smok-
ing cessation.
More severe neutrophilic inflammation in asthma has
been associated with a reduced corticosteroid treatment
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neutrophilic inflammation that we observed in ex- and
current-smokers may be a possible explanation for the re-
duced short-term corticosteroid treatment response in ex-
and current-smokers. Support for the hypothesis that the
type of inflammation in ex- and current-smokers influ-
ences the corticosteroid treatment response is provided by
our observation that smoking status was not independ-
ently associated with improvement in FEV1 %predicted,
whereas less eosinophilic inflammation in sputum and
blood was independently associated with lower im-
provement in FEV1 %predicted, both after 2-week and
after 1-year ICS treatment. In addition, higher levels of
blood neutrophils were also independently associated with
lower improvement in FEV1 %predicted after 2-week ICS
treatment. Interestingly, after 1-year ICS treatment there
were no longer any significant differences in inflammation
between ex-, current- or never-smokers (Additional file 1:
Table S5). This suggests that long-term ICS treatment is
able to correct the inflammatory differences in ex- and
current-smokers, thereby normalizing their ICS treatment
response. Other possible explanations for a lower cortico-
steroid responsiveness in ex- and current-smokers are epi-
genetic changes, e.g. reduced expression of histone
deacetylases (HDAC) [26] and DNA methylation [27],
more expression of the less active β isoform of the gluco-
corticoid receptor [28-30] and increased expression of
pro-inflammatory transcription factors, such as nuclear
factor-kappa B and activator protein 1 [31,32]. Finally, NO
in cigarette smoke reduces the affinity of the glucocortic-
oid receptor for corticosteroids and reduces the binding of
corticosteroids to the glucocorticoid receptor [33].
There are several strengths to our study. Our patients
were extensively characterized, including lung function,
bronchial hyperresponsiveness and inflammation in spu-
tum and blood, at baseline and after 2-weeks and 1-year
treatment with ICS. Our study also has some limitations.
First, we performed post-hoc analyses on data from a
study that was not originally designed to investigate the
effects of smoking on inflammation or corticosteroid
treatment response. Our study was originally a three-
arm study (Figure 1). However, in the 2-week treatment
analyses we included only patients treated with ICS, and
in the 1-year treatment analyses we excluded one group
of patients who were treated according to a program
with step-down and eventually complete discontinuation
of corticosteroids, which is not in agreement with the
current guidelines. Due to this study design, the short-
and long-term corticosteroid response was not investi-
gated in the same groups. In this context, it is important
to mention that the randomization of the study was
performed with minimization for smoking status, age,
previous dose of ICS, FEV1 %predicted, reversibility after
200 μg of salbutamol, PC20 methacholine, and serumIgE. This minimization ensures comparable treatment
arms with minimal baseline differences. Second, current-
and never-smokers were significantly younger than ex-
smokers and therefore we had to adjust for age in all
analyses.
Conclusions
In conclusion, ex- and current-smokers have a different
type of inflammation with less eosinophils and more
neutrophils in their blood and sputum. These differences
in the type of inflammation were present even several
years after smoking cessation. Although we agree with
the literature that ex- and current-smokers have a
blunted short-term response to ICS, we did not find a
difference in their long-term treatment response. There-
fore, they should not be withheld from ICS treatment.
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